{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:59:06Z","timestamp":1791593946566,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019192","name":"Center for Clinical and Translational Science, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["UL1TR001417"],"award-info":[{"award-number":["UL1TR001417"]}],"id":[{"id":"10.13039\/100019192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL143167"],"award-info":[{"award-number":["K23HL143167"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE18A0-Q"],"award-info":[{"award-number":["GUIMBE18A0-Q"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE20A0-KB"],"award-info":[{"award-number":["GUIMBE20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pupt.2024.102314","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:11:38Z","timestamp":1719929498000},"page":"102314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia"],"prefix":"10.1016","volume":"86","author":[{"given":"Zhongyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie R.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.pupt.2024.102314_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2024.102314_bib2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-062985","article-title":"Delivering a new future for people with cystic fibrosis","volume":"152","author":"Burgener","year":"2023","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.pupt.2024.102314_bib3","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review","volume":"14","author":"Dawood","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jcf.2020.04.010","article-title":"Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment","volume":"19","author":"Guhr Lee","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"11","key":"10.1016\/j.pupt.2024.102314_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112686","article-title":"The role of CYP3A in Health and disease","volume":"10","author":"Klyushova","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib6","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr. Pulmonol."},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/FPC.0000000000000246","article-title":"PharmGKB summary: ivacaftor pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.pupt.2024.102314_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights into patient variability during ivacaftor-lumacaftor therapy in cystic fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.548","article-title":"Can cystic fibrosis patients finally catch a breath with lumacaftor\/ivacaftor?","volume":"101","author":"Schneider","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2024.102314_bib10","unstructured":"Drug Approval Package: Kalydeco (ivacaftor): Food and Drug Administration; [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188s000TOC.cfm."},{"key":"10.1016\/j.pupt.2024.102314_bib11","unstructured":"Orkambi (lumacaftor\/ivacaftor) Oral Tablet: Food and Drug Administration; [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/0206038Orig1s000TOC.cfm."},{"key":"10.1016\/j.pupt.2024.102314_bib12","unstructured":"Symdeko (tezacaftor\/ivacaftor) Oral Tablet: Food and Drug Administration; [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000TOC.cfm."},{"key":"10.1016\/j.pupt.2024.102314_bib13","unstructured":"Drug Approval Package: Trikafta Food and Drug Administration: Food and Drug Administration; [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf."},{"issue":"2","key":"10.1016\/j.pupt.2024.102314_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mc.2940140209","article-title":"Cytochrome P450 2A of nasal epithelium: regulation and role in carcinogen metabolism","volume":"14","author":"B\u00e9r\u00e9ziat","year":"1995","journal-title":"Mol. Carcinog."},{"issue":"3","key":"10.1016\/j.pupt.2024.102314_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/20024091064273","article-title":"Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung","volume":"32","author":"Hukkanen","year":"2002","journal-title":"Crit. Rev. Toxicol."},{"issue":"2","key":"10.1016\/j.pupt.2024.102314_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cbi.2003.12.007","article-title":"Regulation of CYP3A genes in the human respiratory tract","volume":"151","author":"Raunio","year":"2005","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.pupt.2024.102314_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.12688\/f1000research.2-173.v2","article-title":"Regulation of CYP3A genes by glucocorticoids in human lung cells","volume":"2","author":"Roberts","year":"2013","journal-title":"F1000Res"},{"issue":"11","key":"10.1016\/j.pupt.2024.102314_bib19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ppul.26093","article-title":"Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis","volume":"57","author":"Guimbellot","year":"2022","journal-title":"Pediatr. Pulmonol."},{"issue":"8","key":"10.1016\/j.pupt.2024.102314_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.377","article-title":"Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein","volume":"55","author":"Robertson","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.pupt.2024.102314_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/membranes11120923","article-title":"Structure of ABCB1\/P-glycoprotein in the presence of the CFTR potentiator ivacaftor","volume":"11","author":"Barbieri","year":"2021","journal-title":"Membranes"},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1872312812666180328105259","article-title":"Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor","volume":"12","author":"Schneider","year":"2018","journal-title":"Drug Metabol. Lett."},{"key":"10.1016\/j.pupt.2024.102314_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.pupt.2024.102314_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"3","key":"10.1016\/j.pupt.2024.102314_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/children10030554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children"},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib28","first-page":"8","article-title":"Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis","volume":"18","author":"Condren","year":"2013","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib29","doi-asserted-by":"crossref","first-page":"L119","DOI":"10.1152\/ajplung.00639.2020","article-title":"CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling","volume":"321","author":"Anderson","year":"2021","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.01.011","article-title":"Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy","volume":"19","author":"Guimbellot","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2024.102314_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060603","article-title":"Human nasal epithelial organoids for therapeutic development in cystic fibrosis","volume":"11","author":"Liu","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.pupt.2024.102314_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.pupt.2024.102314_bib33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.pupt.2024.102314_bib34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"1\u20132","key":"10.1016\/j.pupt.2024.102314_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000091455","article-title":"X-ray microanalysis of apical fluid in cystic fibrosis airway epithelial cell lines","volume":"17","author":"Kozlova","year":"2006","journal-title":"Cell. Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.pupt.2024.102314_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.13329","article-title":"A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators","volume":"46","author":"Gavioli","year":"2021","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib37","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.jcf.2021.06.001","article-title":"Breast development in a 7 year old girl with CF treated with ivacaftor: an indication for personalized dosing?","volume":"20","author":"Jeyaratnam","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14740338.2016.1165666","article-title":"A safety evaluation of ivacaftor for the treatment of cystic fibrosis","volume":"15","author":"McColley","year":"2016","journal-title":"Expet Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib39","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2024.102314_bib40","series-title":"Dose Adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in Response to Mental Health Side Effects in Adults with Cystic Fibrosis","author":"Spoletini Gg","year":"2022"},{"key":"10.1016\/j.pupt.2024.102314_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120211","article-title":"In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model","volume":"596","author":"Chen","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib42","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2024.102314_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FTD.0000000000000829","article-title":"Quantitative method for the analysis of ivacaftor, hydroxymethyl ivacaftor, ivacaftor carboxylate, lumacaftor, and tezacaftor in plasma and sputum using liquid chromatography with tandem mass spectrometry and its clinical applicability","volume":"43","author":"Vonk","year":"2021","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.pupt.2024.102314_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med. (Engl. Ed.)"},{"issue":"12","key":"10.1016\/j.pupt.2024.102314_bib45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/membranes11120923","article-title":"Structure of ABCB1\/P-glycoprotein in the presence of the CFTR potentiator ivacaftor","volume":"11","author":"Barbieri","year":"2021","journal-title":"Membranes"},{"issue":"5","key":"10.1016\/j.pupt.2024.102314_bib46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2021.06.005","article-title":"Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung","volume":"20","author":"Qiu","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2024.102314_bib47","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"1\u20133","key":"10.1016\/j.pupt.2024.102314_bib48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tox.2008.08.004","article-title":"Expression and induction by rifampicin of CAR- and PXR-regulated CYP2B and CYP3A in liver, kidney and airways of pig","volume":"252","author":"Nannelli","year":"2008","journal-title":"Toxicology"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553924000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553924000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:08:36Z","timestamp":1777608516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553924000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":48,"alternative-id":["S1094553924000300"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102314","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102314"}}